Conduct research on psilocybin and its therapeutic potential. Develop pharmaceutical products based on psilocybin. Now — the numbers.
There is not enough trading history here to call this an established business.
The gap is $6.7M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 20.9× for every dollar of annual profit — around what a business like this usually costs.
Fewer than three analyst price targets were published in the last 12 months, so none is shown.
angles, checked one by one.
The 2 that stand out are on screen; the rest are not shown.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 64% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It met or beat analyst expectations in 6 of the last 6 quarters — consistency is a promise kept.
The stock sits at $0.73. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
The stock trades 64% below its five-year peak.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
The takeaway: MYCOF is profitable in the latest year, after losses in 4 of the 5 years shown. Whether that holds is the question.
Not covered, because the filings we hold do not carry it: the revenue breakdown.